Jan 10 2026

george

Review: Desmopressin Therapy in Bleeding Disorders

Here is a 2025 open-access review that describes DDAVP Rx in hemophilia and VWD:  Reardon B, Pasalic L, Favaloro EJ. A review of desmopressin use in bleeding disorders: an unsung hero? Biomolecules. 2025;15:967. doi: 10.3390/biom15070967. PMID: 40723839; PMCID: PMC12292229. Abstract As a synthetic analogue of vasopressin, desmopressin or DDAVP has well-established hemostatic properties. We present […]

read more

Comments (0)

Bleeding Disorders

Jan 9 2026

george

VWD Type 2a Review

For an update on VWD type 2A, check with your medical library for Seidizadeh O, Baronciani L, Mannucci PM, Peyvandi F. Von Willebrand disease type 2A: an update. Semin Thromb Hemost. 2026. doi: 10.1055/a-2778-9989. PMID: 41453393. Abstract Dysfunctional or quantitatively deficient von Willebrand factor (VWF) underlies von Willebrand disease (VWD), the most common inherited bleeding […]

read more

Comments (0)

Bleeding Disorders

Jan 9 2026

george

Anticoagulation Forum Archived Webinars

Fifth on our alphabetical Hemostasis Agencies list is the Anticoagulation Forum. The forum offers a lengthy list of archived educational webinars that describe a number of antithrombotic therapy issues. Click here for the forum’s webinar selection.

read more

Comments (0)

Anticoagulant Therapy

Jan 1 2026

george

Reprise: Isolated Elevated D-dimer in an Apparently Healthy Individual

This question appeared 12-22-25 on the Diagnostic Equity page:  “My D-dimer was elevated, but my CT scan ruled out a blood clot. What other conditions or factors can cause an elevated D-dimer, and then how should this result be interpreted in the context of my symptoms and overall health?“ This answer was provided by colleague Justin […]

read more

Comments (0)

Fibrinolysis

Dec 31 2025

george

January 2026 Cheat Sheet

Click here for your January 2026 Fritsma Factor Cheat Sheet. If you would like a Cheat Sheet push copy that provides links to all the December, 2025 entries, please complete the Cheat Sheet application on the right. All Fritsma Factor services, sponsored by the PBI family of hemostasis in vitro diagnostic distributors, are free.

read more

Comments (0)

Cheat Sheets

Dec 31 2025

george

January 2026 QQ: Fibrinolysis

Fibrinolysis plays a crucial role in the treatment of thrombosis. The components of fibrinolysis, in no particular order, are plasminogen, plasmin, TPA, TAFI, PAI-1, α2 antiplasmin, FDPs, and D-dimer. Our January 2026 Quick Question in the right column is a quiz that asks, “Which fibrinolysis enzyme digests fibrin?” Please select your answer, and feel free […]

read more

Comments (0)

Fibrinolysis

Dec 30 2025

george

December 2025 QQ Results: Control Proteins

Our December 2025 Quick Question was a quiz that asked, “What plasma control protein acts against FIIa & FXa?” Here’s how our 34 respondents fared… Antithrombin: 27 (79%) Protein C: 5 (15%) Protein S: 1 (3%) Protein Z: 0 TFPI: 1 (3%) We scored well on this question. Antithrombin (AT), when activated by therapeutic heparin […]

read more

Comments (0)

Coagulation Factors

Dec 29 2025

george

Andexanet Alfa Withdrawn from the US Market

Thanks for the heads-up from Dr. Paul Riley, who commented on our December 27, 2025, post, Clinical Research Study: Andexanet Alfa for Enoxaparin Reversal. Here is the press release from AstraZeneca announcing the withdrawal of andexanet alfa from the US market.

read more

Comments (0)

Blog

Dec 27 2025

george

Clinical Trial: Thrombin Generation Test Predicts Breakthrough Bleeding in Emicizumab Prophylaxis

Check with your medical library to obtain this clinical trial pre-publication: Pelzer FJ, Ertekin EI, Oleshko O, et al. Thrombin generation to predict breakthrough bleeding in patients with acquired hemophilia A under emicizumab prophylaxis. Haematologica. 2025. doi: 10.3324/haematol.2025.288115. PMID: 41230703. Abstract Acquired hemophilia A (AHA) is a serious bleeding disorder due to neutralizing autoantibodies against […]

read more

Comments (0)

Bleeding Disorders

Dec 27 2025

george

Clinical Research Study: Andexanet Alfa for Enoxaparin Reversal

Navigate to this open-access article describing andexanet alfa reversal of LMWH: van Haaps TF, Benz AP, Xu L, Middeldorp S, Eikelboom JW, et al. Andexanet alfa for the reversal of the low-molecular-weight heparin enoxaparin. Res Pract Thromb Haemost. 2025;9:103191. doi: 10.1016/j.rpth.2025.103191. PMID: 41141842; PMCID: PMC12552982. Abstract Background Andexanet alfa (andexanet) is the only approved reversal […]

read more

Comments (1)

Anticoagulant Therapy